ClearPoint Neuro, Inc. (CLPT) ClearPoint Neuro, Inc. is a medical technology firm primarily operating within the United States. The company specializes in developing and commercializing sophisticated systems that facilitate minimally invasive brain surgeries, guided by real-time magnetic resonance imaging (MRI) during the procedure. Among its core offerings is the ClearPoint system, designed for the precise placement of deep brain stimulation electrodes, biopsy needles, and for the controlled infusion of medications and laser catheters directly into the brain. It also provides the ClearPoint Neuro Navigation System, which is specifically engineered for MRI suite environments. ClearPoint Neuro maintains strategic partnerships and licensing agreements with prominent institutions and companies, including Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and the University of California, San Francisco. Initially established in 1998 and headquartered in Solana Beach, California, the company operated as MRI Interventions, Inc. before rebranding to ClearPoint Neuro, Inc. in February 2020.
Sector: Surgical & Medical Instruments & Apparatus
Industry: Medical - Devices
ClearPoint Neuro, Inc. NASDAQ:CLPT Healthcare · Medical - Devices
Mkt Cap $342.02M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release ● Major ⚠ 4
ClearPoint Neuro Reports Third Quarter 2026 Results
ClearPoint Neuro reported Q3 2026 revenue of $12.1 million, up 36% year-over-year, boosted by the IRRAflow portfolio acquired with IRRAS in late 2025.
Neurosurgery navigation and therapy revenue grew 59% to $5.4 million and capital equipment/software hit a record $1.7 million, while biologics and drug delivery returned to double-digit growth at $4.9 million.
Profitability remains the weak spot: gross margin fell to 58% from 63%, operating loss widened to $6.3 million, and net loss was $7.5 million ($0.24 per share) as operating expenses grew 23%.
Management guided 2026 revenue to $48-50 million, and the company ended the quarter with $46.2 million in cash after raising $22.0 million via an at-the-market equity program that offset $20.1 million of nine-month operating cash burn.
• 4d ago AI analysis › Press Release
ClearPoint Neuro to Announce Third Quarter 2026 Results October 28, 2026
ClearPoint Neuro will release its 2026 third-quarter financial results on Wednesday, October 28, 2026, after market close.
A live conference call is scheduled for 4:30 p.m. Eastern the same day, with a telephone replay available through November 27, 2026.
The notice contains no financial results; it is a scheduling announcement only.
• 18d ago AI analysis › Press Release ⚠ 3
ClearPoint Neuro Reports Second Quarter 2026 Results
ClearPoint Neuro reported Q2 2026 revenue of $10.9 million, an 18% increase year-over-year, driven by the IRRAflow acquisition and increased disposables sales, though the net loss widened to $11.3 million.
The company adjusted its full-year 2026 revenue guidance to $48.0 million to $52.0 million to prioritize investment in clinical capacity and preclinical services at the new ClearPoint Advanced Laboratories facility rather than traditional sales expansion.
Strategic highlights include a 10-year focused ultrasound partnership with SONOCARE Lab and positive regulatory feedback from biopharma partners, with 10-15 clinical trials expected to enroll in the next 18 months.
• 2mo ago AI analysis › Press Release
ClearPoint Neuro Congratulates Partner Aspen Neuroscience on FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Sasineprocel
ClearPoint Neuro congratulated partner Aspen Neuroscience on receiving FDA RMAT designation for sasineprocel, an autologous cell therapy for Parkinson's disease.
The ClearPoint Neuro Navigation System and SmartFlow Cannula are utilized for the transplantation procedure in Aspen's ASPIRO clinical trial.
This milestone highlights the utility of ClearPoint's platform, which currently supports over 60 biologics and drug delivery partner programs.
• 3mo ago AI analysis › Press Release
ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026
ClearPoint Neuro announced it will release its second quarter 2026 financial results after the market close on August 3, 2026.
The company will host a conference call to review the results at 4:30 p.m. Eastern time on the same day, accessible via webcast or telephone.
A replay of the call will be available until September 2, 2026, for those unable to attend the live broadcast.
• 3mo ago AI analysis › Press Release ⚠ 2
ClearPoint Neuro Enters into 10-year Focused Ultrasound Development Partnership with Sungkyunkwan University, South Korea, Further Expanding Our Drug Delivery Ecosystem and Global Footprint
ClearPoint Neuro announced a 10-year development partnership with Sungkyunkwan University in South Korea to enter the focused ultrasound market.
The company demonstrated successful preclinical delivery of large molecule tracers across the blood-brain barrier using a prototype system built with the university's SONOCARELAB.
This move expands ClearPoint's drug delivery ecosystem, adding focused ultrasound to its existing portfolio of cannulas, catheters, and robotic navigation tools for biopharma partners.
• 5mo ago AI analysis › Press Release ● Major
ClearPoint Neuro Reports First Quarter 2026 Results
accessnewswire.com • 5mo ago Press Release ● Critical
ClearPoint Neuro Announces CE Marking of Velocity Alpha MR High Speed Surgical Drill System, Further Expanding Drug Delivery Ecosystem and Global Footprint
accessnewswire.com • 5mo ago Press Release
ClearPoint Neuro to Announce First Quarter 2026 Results May 13, 2026
ClearPoint Neuro announced that it will release its first quarter 2026 financial results after the market close on Wednesday, May 13, 2026.
The company will host a conference call to review the results at 4:30 p.m. Eastern time on the same day, accessible via webcast or telephone.
A replay of the broadcast will be available online and via telephone until June 12, 2026.
• 6mo ago AI analysis › Press Release ● Critical
ClearPoint Neuro Announces FDA Clearance of the Velocity Alpha(R) MR High Speed Surgical Drill System and First Clinical Use, Further Expanding Our Drug Delivery Ecosystem and Global Footprint
accessnewswire.com • 6mo ago Press Release ● Critical
ClearPoint Neuro Announces Canadian Approval for its Navigation System Further Expanding Our Drug Delivery Ecosystem and Global Footprint
accessnewswire.com • 6mo ago Press Release ● Major
ClearPoint Neuro Reports Fourth Quarter and Full Year 2025 Results
accessnewswire.com • 7mo ago 
